Page 1

RNS Number : 4550W Coiled Therapeutics PLC 28 September 2026 28 September 2026 Coiled Therapeutics plc ( " Coiled Therapeutics " or the " Company " ) Interim Results to 30 June 2026 Coiled Therapeutics plc ( AIM : COIL / OTCQB : COTXF ) , the clinical - stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers , announces its interim results for the six - month period ended 30 June 2026 ( the " Period " or " H1 2026 " ) . Highlights Corporate & Listing . • Completed the acquisition of the exclusive worldwide licence to AO - 252 , changed the Company's name to Coiled Therapeutics plc and transitioned its listing from the Main Market to AIM ⚫ Successfully raised gross proceeds of £ 8.5 million through a placing and subscriptions , providing capital to advance AO - 252 through key clinical and value inflection points in 2026 and 2027 ⚫ Strengthened the Board through the appointments of Dr Sotirios Stergiopoulos as Executive Chairman and Sridhar Vempati as Chief Executive Officer Appointed Dr Andrew Dean as Non - Executive Director in May 2026 , adding significant clinical oncology and drug- development expertise to the Board Appointed Craig Tooman as Independent Non - Executive Director with effect from 25 June 2026 , bringing extensive biotechnology , public - company and capital markets experience • Established a Medical Advisory Board in June 2026 , appointing Professor Guru Sonpavde , MD and Dr Alexander Spira , MD PhD FACP as founding members to support AO - 252's clinical strategy and indication expansion Appointed Dr Ozgur Sahin as Scientific Advisor in June 2026 , strengthening the scientific expertise supporting AO - 252's development Clinical In April 2026 , the Company reported positive Phase I clinical data for its lead asset AO - 252 , a first - in - class , orally administered small - molecule TACC3 inhibitor , from the ongoing study NCT06136884 : 0 An 80 % Clinical Benefit Rate ( CBR ) was observed in patients receiving twice - daily dosing , compared with 40 % in the once - daily dosing cohort ⚫ 80 % of evaluable patients receiving twice - daily dosing achieved tumour stabilisation or regression sustained for six months or more , compared with a two - to - three - month duration typically achieved with salvage therapy in heavily pre - treated patients ⚫ No serious adverse effects were reported , and importantly the Maximum Tolerated Dose ( MTD ) has not yet been reached , allowing dose escalation to continue ⚫ Patients had received a median of five prior lines of therapies , confirming positive activity in the heavily pre - treated population Post period end ⚫ In July 2026 , the Company announced the development of a next - generation lipid - based softgel formulation of AO - 252 , designed to improve drug exposure and deliver more consistent , dose - proportional absorption ahead of planned Phase I / II dose - expansion cohorts in ovarian and prostate cancer